About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT04119557

A Study of LY3471851 in Participants With Psoriasis

The main purpose of this study is to learn more about the safety of LY3471851 when given by injection just under the skin to participants with psoriasis. The study will last up to 48 weeks and may inc...

Lead sponsor: Nektar Therapeutics•24 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Nektar Therapeutics

Collaborators

Eli Lilly and Company

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Have a confirmed diagnosis of psoriasis for at least 6 months
•Have active psoriasis plaques according to study- specific criteria
•Be willing and able to undergo skin biopsies

Exclusion Criteria

•Have received certain topical medications for psoriasis within 14 days prior to baseline
•Have received certain systemic medications for psoriasis within 4 weeks prior to baseline
•Have received LY3471851 previously

Related studies

RECRUITINGPhase 2

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07474792 · Plaque Psoriasis

RECRUITINGPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT06857942 · Psoriasis, Overweight or Obesity

RECRUITINGPhase 3

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453 · Plaque Psoriasis

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

NCT07471048 · Psoriasis

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234 · Psoriasis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 20, 2024Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment30

Start dateNov 2019

Last updatedFeb 20, 2024

Condition

Locations shown

Arkansas Research Trials, LLC

North Little Rock, Arkansas

California Dermatology & Clinical Research Institute

Encinitas, California

Center For Dermatology Clinical Research, Inc.

Fremont, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions